Pay in 4 interest-free payments of $6.83 Learn more
Ships within 48 hours · Estimated delivery Sep 21 - Sep 26
Its robust GH-releasing activity is well-documented across decades of research, and its preclinical cardioprotective profile remains one of the most intriguing areas of ongoing investigation
For Dihexa to progress in Alzheimer's research, several conditions would need to be met: Earlier intervention: Testing in cognitively normal individuals at high risk, or mild cognitive impairment, rather than established dementia Bioavailability optimization: Development of oral formulations with superior brain penetration, or better-tolerated intravenous regimens Combination approaches: Testing Dihexa alongside amyloid-targeting drugs or tau-focused therapeutics Mechanism refinement: Understanding which aspects of HGF signalling are beneficial versus which drive cancer risk concerns Patient stratification: Identifying subgroups (by genetics, biomarker status, disease stage) most likely to respond Dose optimization: The LIFT-AD trial used specific doses
In one study, only 17.6% of mice treated with aspirin developed invasive pancreatic cancer, compared to 60% in untreated controls
These findings suggest that BPC-157 may serve as a useful molecular tool for examining signaling events related to connective tissue integrity and cellular stress adaptation
Epub 2006 30 de noviembre
US$ 27.36
US$ 21.91
US$ 24.36
US$ 25.64
US$ 25.35
US$ 26.06
